aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:LIFE
- CUSIP: 53217V10
- Web: www.atyrpharma.com
Capitalization:- Market Cap: $96.55 million
- Outstanding Shares: 23,839,000
Average Prices:- 50 Day Moving Avg: $3.43
- 200 Day Moving Avg: $3.43
- 52 Week Range: $2.10 - $4.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.23
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.68 per share
- Price / Book: 2.41
Profitability:- EBIDTA: ($50,670,000.00)
- Return on Equity: -91.30%
- Return on Assets: -70.74%
Debt:- Debt-to-Equity Ratio: 0.29%
- Current Ratio: 6.13%
- Quick Ratio: 6.13%
Misc:- Average Volume: 105,243 shs.
- Beta: 3.76
- Short Ratio: 13.67
Frequently Asked Questions for aTyr Pharma (NASDAQ:LIFE)
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How were aTyr Pharma's earnings last quarter?
aTyr Pharma, Inc. (NASDAQ:LIFE) posted its quarterly earnings results on Monday, August, 14th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.06. View aTyr Pharma's Earnings History.
When will aTyr Pharma make its next earnings announcement?
Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2017?
4 analysts have issued twelve-month target prices for aTyr Pharma's stock. Their forecasts range from $2.85 to $7.00. On average, they anticipate aTyr Pharma's share price to reach $4.46 in the next year. View Analyst Ratings for aTyr Pharma.
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include Merrimack Pharmaceuticals (MACK), Compugen (CGEN), Advaxis (ADXS), Chromadex Corp (CDXC), OncoMed Pharmaceuticals (OMED), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Genocea Biosciences (GNCA), Pluristem Therapeutics (PSTI), Oramed Pharmaceuticals (ORMP), GTx (GTXI), Regulus Therapeutics (RGLS), Silence Therapeutics plc (SLN), Novelion Therapeutics (NVLN), Matinas BioPharma Holdings (MTNB), BioLineRx (BLRX), CASI Pharmaceuticals (CASI) and CTI BioPharma Corp. (CTIC).
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the folowing people:
- John K. Clarke, Independent Chairman of the Board
- John D. Mendlein Ph.D., Chief Executive Officer, Director
- John T. Blake, Senior Vice President - Finance
- David John King Ph.D., Senior Vice President - Research
- Grove Matsuoka, Senior Vice President, Product Programs and Planning
- Ashraf Amanullah Ph.D., Vice President, Biologics Development and Manufacturing
- Sanuj K. Ravindran M.D., Chief Business Officer
- Sanjay S. Shukla M.D., Chief Medical Officer
- Timothy P. Coughlin CPA, Director
- Jeffrey S. Hatfield, Director
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
Who owns aTyr Pharma stock?
aTyr Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.94%), EcoR1 Capital LLC (9.63%), Vanguard Group Inc. (1.83%), Dimensional Fund Advisors LP (0.24%) and Northern Trust Corp (0.15%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.
Who bought aTyr Pharma stock? Who is buying aTyr Pharma stock?
aTyr Pharma's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.
How do I buy aTyr Pharma stock?
Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is aTyr Pharma's stock price today?
One share of aTyr Pharma stock can currently be purchased for approximately $4.05.
MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for aTyr Pharma (NASDAQ:LIFE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.25) |
| Consensus Price Target: | $4.46 (10.19% upside) |
Analysts' Ratings History for aTyr Pharma (NASDAQ:LIFE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/7/2017 | Piper Jaffray Companies | Initiated Coverage | Overweight -> Overweight | $7.00 | High |  |
| 8/15/2017 | BMO Capital Markets | Set Price Target | Hold | $4.00 | High | |
| 3/20/2017 | Citigroup Inc. | Boost Price Target | Neutral | $3.00 -> $4.00 | Medium | |
| 3/18/2017 | J P Morgan Chase & Co | Reiterated Rating | Hold | | Medium | |
| 3/31/2016 | William Blair | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for aTyr Pharma (NASDAQ:LIFE)Earnings History by Quarter for aTyr Pharma (NASDAQ LIFE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | | | | | | N/A | |
| 8/14/2017 | Q2 2017 | ($0.57) | ($0.51) | | | View | N/A | |
| 5/11/2017 | Q1 2017 | ($0.50) | ($0.56) | | | View | N/A | |
| 11/14/2016 | Q3 2016 | ($0.67) | ($0.58) | | | View | N/A | |
| 8/10/2016 | Q216 | ($0.71) | ($0.65) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.70) | ($0.68) | | | View | N/A | |
| 3/30/2016 | Q4 | ($0.52) | ($0.70) | | | View | N/A | |
| 11/10/2015 | Q3 | ($0.48) | ($0.48) | | | View | N/A | |
| 8/12/2015 | Q215 | ($0.53) | ($0.74) | | | View | N/A | |
| 6/18/2015 | Q115 | ($0.41) | ($0.38) | | | View | N/A | |
| 11/5/2013 | Q313 | $0.97 | $1.02 | $926.10 million | $936.00 million | View | N/A | |
| 7/31/2013 | Q2 2013 | $0.96 | $0.72 | $952.06 million | $944.00 million | View | N/A | |
| 5/2/2013 | Q1 2013 | $1.04 | $1.07 | $958.56 million | $963.00 million | View | N/A | |
| 2/4/2013 | Q4 2012 | $1.11 | $1.11 | $988.85 million | $998.90 million | View | N/A | |
| 11/1/2012 | Q312 | $0.89 | $0.92 | $907.91 million | $911.00 million | View | N/A | |
| 7/31/2012 | | $0.97 | $0.96 | | | View | N/A | |
| 2/7/2012 | | $1.04 | $1.06 | | | View | N/A | |
| 10/25/2011 | | $0.88 | $0.94 | | | View | N/A | |
| 7/28/2011 | | $0.95 | $0.89 | | | View | N/A | |
| 4/26/2011 | | $0.85 | $0.85 | | | View | N/A | |
| 2/3/2011 | | $0.87 | $0.90 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for aTyr Pharma (NASDAQ:LIFE)2017 EPS Consensus Estimate: ($2.08)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.49) | ($0.49) | ($0.49) |
| Q2 2017 | 1 | ($0.50) | ($0.50) | ($0.50) |
| Q3 2017 | 1 | ($0.53) | ($0.53) | ($0.53) |
| Q4 2017 | 1 | ($0.56) | ($0.56) | ($0.56) |
(Data provided by Zacks Investment Research)
Dividend History for aTyr Pharma (NASDAQ:LIFE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for aTyr Pharma (NASDAQ:LIFE)Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 46.66%
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/31/2017 | John Mendlein | CEO | Buy | 37,736 | $2.65 | $100,000.40 | |
| 8/31/2017 | Paul Schimmel | Director | Buy | 94,336 | $2.65 | $249,990.40 | |
| 4/24/2017 | John Mendlein | CEO | Buy | 124 | $3.00 | $372.00 | |
| 4/20/2017 | John Mendlein | CEO | Buy | 2,552 | $3.00 | $7,656.00 | |
| 12/21/2016 | Paul Schimmel | Director | Buy | 25,000 | $2.28 | $57,000.00 | |
| 12/20/2016 | Ashraf Amanullah | VP | Buy | 11,000 | $2.25 | $24,750.00 | |
| 12/19/2016 | John Mendlein | CEO | Buy | 69,000 | $2.20 | $151,800.00 | |
| 12/16/2016 | Paul Schimmel | Director | Buy | 50,000 | $2.48 | $124,000.00 | |
| 5/11/2016 | Grove Matsuoka | Insider | Buy | 12,412 | $3.04 | $37,732.48 | |
| 4/14/2016 | Paul Schimmel | Director | Buy | 66,219 | $4.18 | $276,795.42 | |
| 4/13/2016 | Paul Schimmel | Director | Buy | 9,835 | $3.85 | $37,864.75 | |
| 4/12/2016 | Paul Schimmel | Director | Buy | 9,127 | $3.71 | $33,861.17 | |
| 4/11/2016 | Paul Schimmel | Director | Buy | 32,659 | $3.57 | $116,592.63 | |
| 4/8/2016 | Paul Schimmel | Director | Buy | 85,000 | $3.22 | $273,700.00 | |
| 4/7/2016 | Paul Schimmel | Director | Buy | 40,000 | $3.19 | $127,600.00 | |
| 4/6/2016 | Paul Schimmel | Director | Buy | 25,000 | $3.20 | $80,000.00 | |
| 4/5/2016 | John Mendlein | CEO | Buy | 2,500 | $3.55 | $8,875.00 | |
| 4/5/2016 | Paul Schimmel | Director | Buy | 25,000 | $3.52 | $88,000.00 | |
| 5/12/2015 | James E Flynn | Insider | Buy | 50,000 | $14.00 | $700,000.00 | |
| 5/12/2015 | Sofinnova Venture Partners Ix, | Major Shareholder | Buy | 320,000 | $14.00 | $4,480,000.00 | |
| 5/29/2013 | David C Uprichard | Director | Sell | 2,010 | $74.04 | $148,820.40 | |
| 5/28/2013 | John A Cottingham | Insider | Sell | 60,000 | $74.03 | $4,441,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for aTyr Pharma (NASDAQ:LIFE)
Latest Headlines for aTyr Pharma (NASDAQ:LIFE)
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.53 EPS
www.americanbankingnews.com - September 19 at 12:26 AM |
| aTyr Pharma, Inc. (LIFE) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - September 17 at 1:32 PM |
| aTyr Pharma, Inc. (LIFE) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - September 16 at 7:44 PM |
| aTyr Pharma, Inc. (LIFE) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - September 15 at 9:50 PM |
| Piper Jaffray Companies Begins Coverage on aTyr Pharma, Inc. (LIFE)
www.americanbankingnews.com - September 10 at 10:14 AM |
| Zacks Investment Research Lowers aTyr Pharma, Inc. (LIFE) to Hold
www.americanbankingnews.com - September 8 at 12:36 AM |
| aTyr Pharma, Inc. (LIFE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - September 7 at 10:26 AM |
 | aTyr Pharma to Present at Two Upcoming Investor Conferences in September
finance.yahoo.com - September 6 at 2:03 AM |
| Insider Buying: aTyr Pharma, Inc. (LIFE) CEO Buys 37,736 Shares of Stock
www.americanbankingnews.com - September 5 at 10:27 PM |
| Insider Buying: aTyr Pharma, Inc. (LIFE) Director Buys 94,336 Shares of Stock
www.americanbankingnews.com - September 5 at 10:26 PM |
 | aTyr Pharma (LIFE) Reports $45M Private Placement
www.streetinsider.com - August 29 at 1:07 AM |
| aTyr Pharma Announces $45 Million Equity Financing
finance.yahoo.com - August 28 at 8:05 PM |
| [$$] Publicly Traded Rare Disease Drug-Maker aTyr Pharma Gets $46 Million Lift
finance.yahoo.com - August 28 at 8:05 PM |
| aTyr Pharma, Inc. (LIFE) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - August 22 at 11:58 AM |
| Zacks Investment Research Downgrades aTyr Pharma, Inc. (LIFE) to Hold
www.americanbankingnews.com - August 19 at 10:30 AM |
| William Blair Analysts Lift Earnings Estimates for aTyr Pharma, Inc. (LIFE)
www.americanbankingnews.com - August 17 at 8:22 AM |
| aTyr Pharma, Inc. (LIFE) Releases Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - August 15 at 2:38 PM |
| aTyr Pharma, Inc. (LIFE) Given "Hold" Rating at BMO Capital Markets
www.americanbankingnews.com - August 15 at 1:06 PM |
| aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
finance.yahoo.com - August 15 at 1:02 AM |
| Atyr Pharma reports 2Q loss
finance.yahoo.com - August 15 at 1:02 AM |
| aTyr Pharma, Inc. (NASDAQ:LIFE) Expected to Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - August 13 at 2:24 AM |
| aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results
finance.yahoo.com - August 11 at 6:08 AM |
| aTyr Pharma, Inc. (NASDAQ:LIFE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM |
| aTyr Pharma, Inc. (LIFE) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - July 8 at 10:10 PM |
| -$0.57 EPS Expected for aTyr Pharma, Inc. (LIFE) This Quarter
www.americanbankingnews.com - June 29 at 4:29 PM |
| -$0.57 Earnings Per Share Expected for aTyr Pharma Inc (LIFE) This Quarter
www.americanbankingnews.com - June 5 at 2:14 PM |
| aTyr Pharma to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 31 at 6:43 PM |
| aTyr Pharma Inc (LIFE) Receives "Hold" Rating from BMO Capital Markets
www.americanbankingnews.com - May 24 at 11:32 AM |
| aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar
finance.yahoo.com - May 15 at 10:38 AM |
| aTyr Pharma Inc (LIFE) Posts Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - May 12 at 11:48 AM |
 | UPDATE 1-Contract medical research firm INC to buy inVentiv in $4.6 bln deal
www.businessinsider.com - May 11 at 11:47 PM |
 | Contract medical research firm INC to buy inVentiv in $4.6 billion deal
www.cnbc.com - May 11 at 11:47 PM |
| aTyr Pharma Announces First Quarter 2017 Operating Results
finance.yahoo.com - May 11 at 6:46 PM |
| Atyr Pharma reports 1Q loss
finance.yahoo.com - May 11 at 6:46 PM |
| -$0.55 Earnings Per Share Expected for aTyr Pharma Inc (LIFE) This Quarter
www.americanbankingnews.com - May 10 at 12:10 AM |
| aTyr Pharma Inc (LIFE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:18 AM |
| aTyr Pharma (LIFE) Earns Daily News Impact Rating of -0.10
www.americanbankingnews.com - April 28 at 2:44 PM |
| aTyr Pharma (LIFE) Reports Top-Line Results from Resolaris Phase 1b/2 Trial
www.streetinsider.com - April 24 at 7:23 PM |
| aTyr Pharma (LIFE) Earns News Impact Score of -0.12
www.americanbankingnews.com - April 23 at 3:13 PM |
| aTyr Pharma (LIFE) Given Coverage Optimism Rating of -0.06
www.americanbankingnews.com - April 20 at 3:47 PM |
| Zacks: Analysts Expect aTyr Pharma Inc (LIFE) to Post -$0.55 Earnings Per Share
www.americanbankingnews.com - April 19 at 7:56 AM |
| aTyr Pharma (LIFE) Getting Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - April 14 at 1:08 PM |
| aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors
finance.yahoo.com - April 10 at 5:55 PM |
| Short Interest in aTyr Pharma Inc (LIFE) Drops By 9.3%
www.americanbankingnews.com - April 10 at 3:46 PM |
| aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors - Yahoo Finance
finance.yahoo.com - April 4 at 8:02 AM |
| ATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - April 4 at 8:02 AM |
| aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference
finance.yahoo.com - March 29 at 10:10 AM |
| aTyr Pharma Inc (LIFE) Price Target Raised to $4.00 at Citigroup Inc
www.americanbankingnews.com - March 24 at 11:31 AM |
| ATYR PHARMA INC Financials
finance.yahoo.com - March 22 at 6:26 PM |
| aTyr Pharma Inc (LIFE) Given New $4.00 Price Target at Citigroup Inc
www.americanbankingnews.com - March 20 at 12:32 PM |
aTyr Pharma (LIFE) Chart for Sunday, September, 24, 2017
